Raymond James Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.39M Buy
168,424
+68,330
+68% +$1.83M ﹤0.01% 3099
2026
Q2
$2.53M Buy
100,094
+68,171
+214% +$1.5M ﹤0.01% 3320
2026
Q1
$711K Buy
31,923
+11,274
+55% +$269K ﹤0.01% 4106
2025
Q4
$552K Sell
20,649
-4,549
-18% -$109K ﹤0.01% 4202
2025
Q3
$538K Sell
25,198
-4,481
-15% -$106K ﹤0.01% 4082
2025
Q2
$640K Buy
29,679
+1,396
+5% +$25.9K ﹤0.01% 3851
2025
Q1
$470K Sell
28,283
-7,878
-22% -$143K ﹤0.01% 3967
2024
Q4
$664K Buy
+36,161
New +$584K ﹤0.01% 3724

Other funds holding ACAD

Raymond James Financial's ACAD Position: Q3 2026 in Review

Raymond James Financial increased its Acadia Pharmaceuticals (ACAD) stake by 68% in Q3 2026, buying an estimated $1.83M and bringing the position to 168,424 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3099.

Raymond James Financial first reported a position in ACAD in Q4 2024 and has held it in 8 quarters since. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Raymond James Financial held 168,424 shares of Acadia Pharmaceuticals worth $3.39M as of Q3 2026.
  • Raymond James Financial bought 68,330 Acadia Pharmaceuticals shares in Q3 2026, an estimated $1.83M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3099 holding.
  • Raymond James Financial first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.